Literature DB >> 23226803

Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis.

Herlander Marques1, Raquel Catarino, Nelson Domingues, Eliane Barros, Catarina Portela, Maria Inês Almeida, Sandra Costa, Rui Manuel Reis, Rui Medeiros, Adhemar Longatto-Filho.   

Abstract

The Epstein-Barr virus (EBV) is associated with a large spectrum of lymphoproliferative diseases. Traditional methods of EBV detection include the immunohistochemical identification of viral proteins and DNA probes to the viral genome in tumoral tissue. The present study explored the detection of the EBV genome, using the BALF5 gene, in the bone marrow or blood mononuclear cells of patients with diffuse large B-cell lymphomas (DLBCL) and related its presence to the clinical variables and risk factors. The results show that EBV detection in 21.5% of patients is not associated with age, gender, staging, B symptoms, international prognostic index scores or any analytical parameters, including lactate dehydrogenase (LDH) or β-2 microglobulin (B2M). The majority of patients were treated with R-CHOP-like (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone or an equivalent combination) and some with CHOP-like chemotherapy. Response rates [complete response (CR) + partial response (PR)] were not significantly different between EBV-negative and -positive cases, with 93.2 and 88.9%, respectively. The survival rate was also similar in the two groups, with 5-year overall survival (OS) rates of 64.3 and 76.7%, respectively. However, when analyzing the treatment groups separately there was a trend in EBV-positive patients for a worse prognosis in patients treated with CHOP-like regimens that was not identified in patients treated with R-CHOP-like regimens. We conclude that EBV detection in the bone marrow and blood mononuclear cells of DLBC patients has the same frequency of EBV detection on tumoral lymphoma tissue but is not associated with the risk factors, response rate and survival in patients treated mainly with immunochemotherapy plus rituximab. These results also suggest that the addition of rituximab to chemotherapy improves the prognosis associated with EBV detection in DLBCL.

Entities:  

Year:  2012        PMID: 23226803      PMCID: PMC3506762          DOI: 10.3892/ol.2012.913

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

Review 1.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma.

Authors:  Domingo Morales; Brady Beltran; Fernando Hurtado De Mendoza; Luis Riva; Alejandro Yabar; Pilar Quiñones; James N Butera; Jorge Castillo
Journal:  Leuk Lymphoma       Date:  2010-01

3.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

4.  The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.

Authors:  Sarah Park; Jeeyun Lee; Young Hyeh Ko; Arum Han; Hyun Jung Jun; Sang Chul Lee; In Gyu Hwang; Yeon Hee Park; Jin Seok Ahn; Chul Won Jung; Kihyun Kim; Yong Chan Ahn; Won Ki Kang; Keunchil Park; Won Seog Kim
Journal:  Blood       Date:  2007-03-30       Impact factor: 22.113

5.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 6.  Prognostic [corrected] significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature.

Authors:  Semra Paydas; Melek Ergin; Gulsah Seydaoglu; Seyda Erdogan; Sinan Yavuz
Journal:  Leuk Res       Date:  2009-03-16       Impact factor: 3.156

7.  Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.

Authors:  Takashi Oyama; Kazuhito Yamamoto; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Kengo Takeuchi; Toshiyuki Izumo; Shigeo Mori; Koichi Ohshima; Junji Suzumiya; Naoya Nakamura; Masafumi Abe; Koichi Ichimura; Yumiko Sato; Tadashi Yoshino; Tomoki Naoe; Yoshie Shimoyama; Yoshikazu Kamiya; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

8.  Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

Authors:  Gemma Kelly; Andrew Bell; Alan Rickinson
Journal:  Nat Med       Date:  2002-09-03       Impact factor: 53.440

9.  Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations.

Authors:  Sylvia Hoeller; Alexandar Tzankov; Stefano A Pileri; Philip Went; Stephan Dirnhofer
Journal:  Hum Pathol       Date:  2009-11-13       Impact factor: 3.466

10.  Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma.

Authors:  Rocío Hassan; Lídia Roxana White; Claudio Gustavo Stefanoff; Deilson Elgui de Oliveira; Fabricio E Felisbino; Claudete Esteves Klumb; Carlos E Bacchi; Héctor N Seuánez; Ilana R Zalcberg
Journal:  Diagn Pathol       Date:  2006-08-07       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.